Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 401-210-9 | CAS number: 83708-14-9 BEHENYLKETENDIMER; HERCULES PMC D-532; PMC D-532
Endpoint summary
Administrative data
Description of key information
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 20 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 1 000 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
Additional information
In the oral 90 days test a NOAEL of 20 mg/kg bw/d was determined. At the higher test doses (200 and 2000 mg/kg be/d) several adverse effects was observed. Signs were ALT and AST levels, increased relative liver weight (associated with centrolobular hypertrophy), increased spleen weight, histiocytosis of the mesenteric lymph nodes and liver, necrosis, inflammation and hypertrophy of the liver)
Justification for selection of repeated dose toxicity dermal - systemic effects endpoint:
In a 28 days test on rats via the dermal route a NOAEL of 1 g/kg bw/d was found. At this dose no clinical signs, no deaths and no effects on heamatological, biochemical and urinanalysis parameters were seen. The necropsy did not reveal any abnormalities. The adrenal gland weight was slightly increased but did not demonstrate treatment related changes.
Justification for classification or non-classification
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
